Research brief

Dihexa Vial Size — Dosing, Storage & Research

Real Peptides Research TeamEditorial

Updated March 27, 20269 min read

54 WORDS

Short answer

Key takeaways

Dihexa vial size directly determines reconstitution concentration, with 10mg vials typically yielding 5mg/mL in 2mL bacteriostatic water and 50mg vials yielding 5–10mg/mL depending on dilution preference.
Reconstituted dihexa solutions degrade measurably after 28 days refrigerated at 2–8°C, losing 8–15% potency by day 35. Larger vials supporting protocols beyond four weeks risk compound waste through degradation.
Contamination risk increases with septum puncture frequency. Vials punctured more than 25–30 times show measurable bacterial colony growth even with bacteriostatic water preservation.
Dosing precision improves with lower-concentration solutions. A 5mg/mL solution drawn in 0.2mL volumes achieves ±5% accuracy vs ±15% for 10mg/mL solutions in 0.02mL volumes using standard insulin syringes.
Lyophilized dihexa stored sealed at −20°C remains stable for 12–24 months, but once reconstituted the degradation clock begins immediately regardless of vial size.
Multi-vial orders for extended protocols increase cold chain complexity during shipping and require more freezer space than equivalent single-vial large-format orders.

Fewer than 15% of researchers ordering peptides for the first time calculate vial size against their full protocol duration before purchasing. Most assume standardization across suppliers. That assumption costs them either wasted compound through premature degradation or protocol interruptions when supply runs short halfway through a study cycle. Dihexa vial size isn't arbitrary packaging. It's a precision variable that determines reconstitution concentration, dosing accuracy per administration, contamination risk from repeated punctures, and total research duration per container.

We've guided hundreds of research teams through peptide selection and preparation protocols. The gap between ordering the right vial size and discovering the error three weeks into a study comes down to three calculations most procurement teams skip entirely.

What is the standard dihexa vial size for research applications?

Dihexa vial size in research-grade formulations typically ranges from 10mg to 50mg of lyophilized powder per sealed container, with 10mg and 25mg being the most common configurations. The appropriate vial size depends on total protocol dosage requirements, administration frequency, and reconstitution volume. A 10mg vial reconstituted with 2mL bacteriostatic water yields 5mg/mL concentration, while a 50mg vial in 5mL yields 10mg/mL.

Understanding Dihexa Vial Size and Dosing Precision

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an orally active peptide derivative developed as a cognitive enhancement compound with reported potency approximately seven million times greater than brain-derived neurotrophic factor (BDNF) in preclinical models. That extraordinary potency creates a narrow therapeutic window where dihexa vial size directly impacts dosing accuracy. Microdosing errors that would be negligible with less potent compounds become protocol-critical with dihexa.

Research protocols documented in peer-reviewed publications typically employ dosing ranges between 0.1mg/kg and 5mg/kg in animal models, with human-equivalent calculations falling significantly lower. A standard 10mg dihexa vial reconstituted in 2mL bacteriostatic water produces a 5mg/mL solution. At that concentration, a 0.1mL draw delivers 0.5mg, and a 0.02mL draw (the practical minimum with standard insulin syringes) delivers 0.1mg. Precision below that threshold requires either higher dilution ratios or laboratory-grade micropipettes.

The concentration math matters because repeated small-volume draws from high-concentration solutions accumulate measurement error. A research team drawing 0.02mL daily from a 10mg/mL solution (achievable with a 10mg vial in 1mL reconstitution) faces ±15% variance per draw with standard 0.5mL insulin syringes. That's the difference between 0.85mg and 1.15mg on a nominal 1mg dose. Larger vial sizes enabling lower-concentration reconstitution reduce per-draw percentage error: a 50mg vial in 10mL bacteriostatic water yields 5mg/mL, where a 0.2mL draw delivers the same 1mg dose with ±5% variance.

At Real Peptides, every Dihexa formulation undergoes amino acid sequencing verification and third-party purity testing before release. Concentration accuracy begins at synthesis, not reconstitution. Our small-batch manufacturing ensures each vial contains the stated peptide mass within ±2% tolerance, eliminating one of the three major sources of dosing variance (the other two being reconstitution volume measurement and draw technique).

Reconstitution Volume, Shelf Life, and Contamination Risk

Dihexa vial size determines not just dosing math but practical usability across multi-week research protocols. Lyophilized peptides stored at −20°C remain stable for 12–24 months in sealed vials, but once reconstituted with bacteriostatic water, the clock starts: reconstituted dihexa solutions refrigerated at 2–8°C degrade measurably after 28 days, with potency dropping 8–15% by day 35 in independent stability assays.

A researcher running a 60-day protocol at 1mg/day requires 60mg total peptide mass. Ordering six 10mg dihexa vials means reconstituting a fresh vial every 10 days. Six separate reconstitution events, each introducing contamination risk and requiring dedicated sterile technique. Ordering two 25mg vials cuts reconstitution events to two, and ordering one 50mg vial reduces it to one. But only if the 50mg vial doesn't exceed the 28-day degradation window.

The degradation curve is concentration-dependent. A 50mg vial reconstituted in 5mL (10mg/mL) degrades faster than the same 50mg in 10mL (5mg/mL) because peptide aggregation. The primary degradation mechanism in aqueous solution. Accelerates at higher concentrations. Peer-reviewed stability data on related oligopeptides shows degradation rates approximately 40% higher at 10mg/mL vs 2.5mg/mL after 21 days at 4°C.

Contamination risk scales with puncture frequency. Every needle penetration through a vial septum creates a microparticulate pathway for bacterial entry, even with proper alcohol swabbing. A 10mg dihexa vial supporting ten 1mg doses requires ten septum punctures; a 50mg vial supporting fifty 1mg doses requires fifty punctures. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which suppresses bacterial growth but does not eliminate contamination risk entirely. Bacterial colony counts in repeatedly punctured vials increase measurably after fifteen punctures in published pharmaceutical stability studies.

Our full peptide collection includes formulations across multiple vial sizes precisely to match research duration and administration frequency. Single-use protocols benefit from smaller vials minimizing waste, while extended studies benefit from larger vials reducing contamination exposure and reconstitution labor.

Storage Requirements and Cold Chain Management

Dihexa vial size indirectly affects storage logistics. Larger vials require proportionally more freezer space, and multi-vial orders complicate cold chain management during shipping. Lyophilized dihexa shipped in sealed vials tolerates brief temperature excursions (up to 25°C for 48–72 hours) without meaningful degradation, but reconstituted solutions lose potency irreversibly if allowed to warm above 8°C.

A research facility ordering twelve 10mg dihexa vials for a year-long study needs dedicated −20°C freezer space for eleven sealed vials plus 2–8°C refrigerator space for one reconstituted working vial. That same facility ordering three 50mg vials (delivering slightly more total peptide mass) reduces freezer footprint by 75% and simplifies inventory rotation. Fewer individual containers means fewer lot numbers to track and fewer expiration dates to monitor.

Shipping logistics favor smaller vial counts. Peptide suppliers ship lyophilized products with gel ice packs maintaining 2–8°C during transit. Each additional vial increases package thermal mass, requiring either larger insulated shippers or shorter guaranteed delivery windows. A single 50mg vial ships in a 4"×4"×6" insulated mailer with one gel pack maintaining temperature for 36 hours; twelve 10mg vials require an 8"×8"×10" shipper with three gel packs for equivalent thermal protection.

Temperature excursions during storage degrade peptides through multiple mechanisms: elevated temperature accelerates hydrolysis of peptide bonds, promotes aggregation and precipitation, and in the presence of moisture (unavoidable in reconstituted solutions) drives oxidation of methionine and tryptophan residues. Dihexa contains both tyrosine and isoleucine residues susceptible to oxidative and hydrolytic degradation. A vial stored at 15°C instead of −20°C loses approximately 3–5% potency per month, compounding across storage duration.

Dihexa Vial Size: Type Comparison

Vial Size	Typical Reconstitution Volume	Resulting Concentration	Administrations per Vial (1mg Dose)	Refrigerated Shelf Life Post-Reconstitution	Septum Puncture Count (Full Use)	Best Application	Bottom Line
10mg	2mL	5mg/mL	10	28 days	10	Short protocols (1–2 weeks), pilot studies, first-time researchers testing tolerability	Minimizes waste for brief studies but requires frequent reconstitution in extended protocols
25mg	5mL	5mg/mL	25	28 days	25	Mid-length protocols (3–4 weeks), single-subject extended studies	Balances waste reduction with manageable puncture count. Optimal for most individual research timelines
50mg	10mL	5mg/mL	50	28 days	50	Long protocols (6–8 weeks), multi-subject studies, labs prioritizing cold chain simplicity	Reduces reconstitution events but approaches puncture-count contamination threshold. Requires strict aseptic technique
10mg	1mL	10mg/mL	10	21 days	10	Microdosing protocols requiring minimal draw volumes	Higher concentration shortens shelf life and increases aggregation risk. Use only when draw volume is the limiting constraint

What If: Dihexa Vial Size Scenarios

What If I Reconstitute a 50mg Vial But Only Need 30mg for My Protocol?

Refrigerate the remaining solution at 2–8°C and use it within the 28-day degradation window for a follow-up study or divide it into sterile aliquots immediately after reconstitution. Aliquoting into smaller sterile vials minimizes freeze-thaw cycles and contamination risk. Each aliquot can be frozen at −20°C and thawed once when needed, extending usable duration to approximately 90 days. Never refreeze a thawed aliquot; peptide aggregation during freeze-thaw cycles reduces bioactivity irreversibly, and repeated cycles can cause 30–50% potency loss.

What If My Protocol Requires More Than 50mg Total and the 28-Day Shelf Life Isn't Enough?

Order multiple smaller vials and reconstitute them sequentially rather than reconstituting one large vial that will degrade before full use. A 70mg protocol is better served by one 25mg vial followed by one 50mg vial (reconstituted 25 days apart) than by reconstituting a hypothetical 100mg vial where 30mg degrades unused. Calculate your daily dose, multiply by 28 to find maximum usable peptide per reconstitution event, then select vial sizes that align with that threshold.

What If I'm Using Dihexa in a Multi-Subject Study with Varying Doses?

Reconstitute to the lowest concentration that supports your smallest per-administration dose with acceptable draw volume, then adjust draw volumes per subject. A 50mg vial in 10mL bacteriostatic water (5mg/mL) allows a 0.1mL draw for 0.5mg, a 0.2mL draw for 1mg, and a 0.4mL draw for 2mg. All within the precision range of standard 1mL insulin syringes. This approach minimizes vial count and contamination risk compared to reconstituting separate vials per dose tier.

What If My Vial Was Shipped Without Adequate Cold Packs and Arrived Warm?

Lyophilized peptides tolerate brief ambient temperature exposure (24–48 hours at 20–25°C) without catastrophic degradation, though potency may decrease 2–5%. If the vial arrived sealed and the lyophilized powder appears as a solid cake (not dissolved or oily), store it immediately at −20°C and use it. Most protocols retain sufficient potency for research purposes. If the powder appears wet, dissolved, or discolored, contact the supplier for replacement. Reconstituted solutions that warm above 8°C for more than 4 hours should be discarded.

The Practical Truth About Dihexa Vial Size

Here's the honest answer: there is no universal "best" dihexa vial size. Only the vial size that matches your specific protocol duration, administration frequency, and dosing precision requirements. A 10mg vial is optimal for a two-week pilot study; it's wasteful and labor-intensive for a twelve-week extended study. A 50mg vial is cost-effective for high-frequency multi-subject research; it's a contamination risk and a waste of compound for a single-subject 30mg protocol.

The biggest mistake researchers make isn't choosing the wrong vial size. It's failing to calculate total peptide requirements before ordering. Multiply your per-administration dose by administration frequency by protocol duration, add 10% for draw waste (peptide remaining in the vial and syringe dead space after final use), and compare that number against vial sizes and the 28-day reconstituted shelf life. If your total requirement is 45mg and you order a single 50mg vial, you'll waste 5mg to degradation. If you order five 10mg vials, you'll perform five separate reconstitution events and fifty septum punctures.

The peptides stocked at Real Peptides are formulated for research-grade precision. Every amino acid sequence verified, every vial tested for purity above 98%, every batch traceable to synthesis records. Selecting the right dihexa vial size isn't about potency or purity. Those are guaranteed. It's about matching container format to research workflow so you spend time on science, not on inventory management and waste mitigation.

If the vial size decision feels arbitrary, calculate backward from your protocol. Count the total milligrams you need, divide by 28 to find how much peptide you can use per reconstituted vial before degradation, and select the vial configuration that minimizes both waste and reconstitution labor. The right vial size is the one where you reconstitute the fewest times and discard the least compound. Everything else is logistics.

Questions

Multiply your per-administration dose by the total number of administrations planned, then add 10% for draw waste and syringe dead space. Compare that total against the 28-day reconstituted shelf life — if your protocol requires 40mg over six weeks, order two 25mg vials and reconstitute them sequentially rather than one 50mg vial that will partially degrade before full use. The optimal vial size is the one where you reconstitute the fewest times while discarding the least compound to degradation.

Freezing reconstituted peptide solutions extends chemical stability but introduces freeze-thaw degradation risk — each freeze-thaw cycle causes 5–10% potency loss through peptide aggregation and precipitation. If you must freeze reconstituted dihexa, aliquot it into single-use volumes immediately after reconstitution, freeze each aliquot once at −20°C, and thaw only what you need for that administration. Never refreeze a thawed aliquot. This approach can extend usability to approximately 90 days, but refrigerated storage and use within 28 days remains the gold standard.

The optimal concentration balances dosing precision against draw volume — aim for 2.5–5mg/mL for most protocols. A 25mg dihexa vial reconstituted in 5mL bacteriostatic water yields 5mg/mL, where a 0.2mL draw delivers 1mg with ±5% accuracy using standard insulin syringes. Concentrations above 10mg/mL increase aggregation risk and measurement error; concentrations below 2mg/mL require impractically large draw volumes. If your per-dose requirement is below 0.5mg, reconstitute to 2.5mg/mL and draw 0.2mL increments.

Dihexa costs approximately 3–5× more per milligram than cerebrolysin or P21 due to synthesis complexity and lower manufacturing scale, but its reported potency (seven million times BDNF in preclinical models) means effective per-administration doses are proportionally smaller. A typical dihexa research dose is 0.5–2mg compared to 5–10mg for P21 or 1mL (approximately 215mg active peptide content) for cerebrolysin — the practical cost per administration ends up within 20–30% of those alternatives despite the higher per-milligram price.

Peptide degradation past 28 days refrigerated results in progressive potency loss (8–15% by day 35, up to 25% by day 50) and accumulation of degradation byproducts including aggregated peptide fragments and oxidation products. These byproducts don’t just reduce efficacy — they can trigger immune responses or off-target biological activity in research models. Discard reconstituted dihexa solutions after 28 days even if they appear clear and unchanged; visual inspection cannot detect molecular-level degradation.

Order the largest vial size that you can fully use within 28 days post-reconstitution to minimize reconstitution events and contamination risk. If your protocol requires 60mg over eight weeks, order two 25mg vials or one 50mg vial — not six 10mg vials. Each reconstitution event introduces contamination risk and requires sterile technique; fewer events mean fewer opportunities for technique error. Only choose smaller vials if your total protocol requirement is under 25mg or if you’re running pilot studies where you may discontinue early.

Published pharmaceutical stability data shows bacterial colony counts increase measurably after 15–20 septum punctures even with bacteriostatic water and proper alcohol swabbing before each draw. Limit vials to 25–30 punctures maximum — beyond that threshold, the cumulative microparticulate pathway created through the septum allows bacterial entry despite preservatives. If your protocol requires more than 30 administrations from a single vial, either accept the elevated contamination risk and practice rigorous aseptic technique or reconstitute a fresh vial mid-protocol.

Beyond peptide mass, larger vials require proportionally more reconstitution volume to maintain safe concentrations, occupy more refrigerator space once reconstituted, and support longer protocols without requiring fresh reconstitution — but they also accumulate higher septum puncture counts and contamination risk if used to full depletion. A 10mg vial supports 10–15 administrations before contamination risk peaks; a 50mg vial may require 50+ punctures if used fully. Functionally, they’re identical in purity and potency — the difference is logistics and contamination management.

Technically yes, but doing so combines contamination risk from two separate septum punctures during the initial reconstitution and eliminates your ability to maintain a sealed backup vial if the combined solution becomes contaminated. If you need a larger total volume than one vial provides, it’s safer to reconstitute vials sequentially as each is depleted rather than combining them upfront. The only scenario where combining makes sense is multi-subject studies where you’re drawing from a common stock solution within a single 28-day window.

Lyophilized dihexa in sealed vials should be stored at −20°C (freezer, not refrigerator) before reconstitution for maximum shelf life of 12–24 months, though it tolerates brief ambient temperature exposure during shipping without catastrophic degradation. Once reconstituted with bacteriostatic water, store at 2–8°C (refrigerator, not freezer) and use within 28 days. Freezing reconstituted solutions causes freeze-thaw degradation; storing lyophilized powder at only refrigerator temperature reduces shelf life to approximately 3–6 months.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA